Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

While CF remains Vertex's primary revenue driver, the company is actively working to diversify its portfolio. Several key pipeline programs ... beyond small molecule drugs. Vertex's continued ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

WASHINGTON (AP) — Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction ...

While CF remains Vertex's primary revenue driver, the company is actively working to diversify its portfolio. Several key pipeline programs and potential ... new avenues for growth beyond small ...

Clarametyx and Kineticos Life Sciences announced an investment by the Kineticos AMR Accelerator Fund ("KAMRA Fund.") ...

Rising interest rates, challenges in the U.S. healthcare system, and the inherent risks of drug development ... with its CF franchise providing a rock-solid foundation while multiple late-stage ...

Strategically focused pipeline optimizes resource allocation ... and ongoing support from the Cystic Fibrosis Foundation and collaboration with Therapeutics Development Network, the Company ...